The next click in antibody drug conjugate development.

The clinical success of antibody drug conjugates has been shaped by the promise of delivering cytotoxic payloads precisely to tumors while minimizing systemic exposure. Simó and colleagues aim to improve on conventional ADC delivery by decoupling tumor localization from payload delivery to enhance pharmacokinetics and addressing antigen heterogeneity by enabling dual targeting.